Getting your player ready...
The Food and Drug Administration on Tuesday unexpectedly rejected what appeared to be the most promising candidate among a class of new diet drugs, wiping out hopes for a new medication to fight obesity any time soon.
Orexigen Therapeutics Inc. said the FDA is concerned about the heart side effects of its drug Contrave and will require a new study, a costly undertaking that may prove too burdensome for the small drugmaker.
